Cargando…
LncRNA IPW inhibits growth of ductal carcinoma in situ by downregulating ID2 through miR-29c
BACKGROUND: Ductal carcinoma in situ (DCIS) of breast is the noninvasive lesion that has propensity to progress to the malignant form. At present, it is still unknown which lesions can potentially progress to invasive forms. In this study, we aimed to identify key lncRNAs involved in DCIS growth. ME...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8787949/ https://www.ncbi.nlm.nih.gov/pubmed/35078502 http://dx.doi.org/10.1186/s13058-022-01504-4 |
_version_ | 1784639453350854656 |
---|---|
author | Deshpande, Ravindra Pramod Sharma, Sambad Liu, Yin Pandey, Puspa Raj Pei, Xinhong Wu, Kerui Wu, Shih-Ying Tyagi, Abhishek Zhao, Dan Mo, Yin-Yuan Watabe, Kounosuke |
author_facet | Deshpande, Ravindra Pramod Sharma, Sambad Liu, Yin Pandey, Puspa Raj Pei, Xinhong Wu, Kerui Wu, Shih-Ying Tyagi, Abhishek Zhao, Dan Mo, Yin-Yuan Watabe, Kounosuke |
author_sort | Deshpande, Ravindra Pramod |
collection | PubMed |
description | BACKGROUND: Ductal carcinoma in situ (DCIS) of breast is the noninvasive lesion that has propensity to progress to the malignant form. At present, it is still unknown which lesions can potentially progress to invasive forms. In this study, we aimed to identify key lncRNAs involved in DCIS growth. METHODS: We employ disease-related lncProfiler array to identify IPW in specimens of DCIS and matching control samples and validate the observations in three DCIS-non-tumorigenic cell lines. Further, we examine the mechanism of IPW action and the downstream signaling in in vitro and in vivo assays. Importantly, we screened a library containing 390 natural compounds to identify candidate compound selectively inhibiting IPW low DCIS cells. RESULTS: We identified lncRNA IPW as a novel tumor suppressor critical for inhibiting DCIS growth. Ectopic expression of IPW in DCIS cells strongly inhibited cell proliferation, colony formation and cell cycle progression while silencing IPW in primary breast cells promoted their growth. Additionally, orthotropic implantation of cells with ectopic expression of IPW exhibited decreased tumor growth in vivo. Mechanistically, IPW epigenetically enhanced miR-29c expression by promoting H3K4me3 enrichment in its promoter region. Furthermore, we identified that miR-29c negatively regulated a stemness promoting gene, ID2, and diminished self-renewal ability of DCIS cells. Importantly, we screened a library containing 390 natural compounds and identified toyocamycin as a compound that selectively inhibited the growth of DCIS with low expression of IPW, while it did not affect DCIS with high IPW expression. Toyocamycin also suppressed genes associated with self-renewal ability and inhibited DCIS growth in vivo. CONCLUSION: Our findings revealed a critical role of the IPW-miR-29c-ID2 axis in DCIS formation and suggested potential clinical use of toyocamycin for the treatment of DCIS. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13058-022-01504-4. |
format | Online Article Text |
id | pubmed-8787949 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-87879492022-02-03 LncRNA IPW inhibits growth of ductal carcinoma in situ by downregulating ID2 through miR-29c Deshpande, Ravindra Pramod Sharma, Sambad Liu, Yin Pandey, Puspa Raj Pei, Xinhong Wu, Kerui Wu, Shih-Ying Tyagi, Abhishek Zhao, Dan Mo, Yin-Yuan Watabe, Kounosuke Breast Cancer Res Research Article BACKGROUND: Ductal carcinoma in situ (DCIS) of breast is the noninvasive lesion that has propensity to progress to the malignant form. At present, it is still unknown which lesions can potentially progress to invasive forms. In this study, we aimed to identify key lncRNAs involved in DCIS growth. METHODS: We employ disease-related lncProfiler array to identify IPW in specimens of DCIS and matching control samples and validate the observations in three DCIS-non-tumorigenic cell lines. Further, we examine the mechanism of IPW action and the downstream signaling in in vitro and in vivo assays. Importantly, we screened a library containing 390 natural compounds to identify candidate compound selectively inhibiting IPW low DCIS cells. RESULTS: We identified lncRNA IPW as a novel tumor suppressor critical for inhibiting DCIS growth. Ectopic expression of IPW in DCIS cells strongly inhibited cell proliferation, colony formation and cell cycle progression while silencing IPW in primary breast cells promoted their growth. Additionally, orthotropic implantation of cells with ectopic expression of IPW exhibited decreased tumor growth in vivo. Mechanistically, IPW epigenetically enhanced miR-29c expression by promoting H3K4me3 enrichment in its promoter region. Furthermore, we identified that miR-29c negatively regulated a stemness promoting gene, ID2, and diminished self-renewal ability of DCIS cells. Importantly, we screened a library containing 390 natural compounds and identified toyocamycin as a compound that selectively inhibited the growth of DCIS with low expression of IPW, while it did not affect DCIS with high IPW expression. Toyocamycin also suppressed genes associated with self-renewal ability and inhibited DCIS growth in vivo. CONCLUSION: Our findings revealed a critical role of the IPW-miR-29c-ID2 axis in DCIS formation and suggested potential clinical use of toyocamycin for the treatment of DCIS. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13058-022-01504-4. BioMed Central 2022-01-25 2022 /pmc/articles/PMC8787949/ /pubmed/35078502 http://dx.doi.org/10.1186/s13058-022-01504-4 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Research Article Deshpande, Ravindra Pramod Sharma, Sambad Liu, Yin Pandey, Puspa Raj Pei, Xinhong Wu, Kerui Wu, Shih-Ying Tyagi, Abhishek Zhao, Dan Mo, Yin-Yuan Watabe, Kounosuke LncRNA IPW inhibits growth of ductal carcinoma in situ by downregulating ID2 through miR-29c |
title | LncRNA IPW inhibits growth of ductal carcinoma in situ by downregulating ID2 through miR-29c |
title_full | LncRNA IPW inhibits growth of ductal carcinoma in situ by downregulating ID2 through miR-29c |
title_fullStr | LncRNA IPW inhibits growth of ductal carcinoma in situ by downregulating ID2 through miR-29c |
title_full_unstemmed | LncRNA IPW inhibits growth of ductal carcinoma in situ by downregulating ID2 through miR-29c |
title_short | LncRNA IPW inhibits growth of ductal carcinoma in situ by downregulating ID2 through miR-29c |
title_sort | lncrna ipw inhibits growth of ductal carcinoma in situ by downregulating id2 through mir-29c |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8787949/ https://www.ncbi.nlm.nih.gov/pubmed/35078502 http://dx.doi.org/10.1186/s13058-022-01504-4 |
work_keys_str_mv | AT deshpanderavindrapramod lncrnaipwinhibitsgrowthofductalcarcinomainsitubydownregulatingid2throughmir29c AT sharmasambad lncrnaipwinhibitsgrowthofductalcarcinomainsitubydownregulatingid2throughmir29c AT liuyin lncrnaipwinhibitsgrowthofductalcarcinomainsitubydownregulatingid2throughmir29c AT pandeypusparaj lncrnaipwinhibitsgrowthofductalcarcinomainsitubydownregulatingid2throughmir29c AT peixinhong lncrnaipwinhibitsgrowthofductalcarcinomainsitubydownregulatingid2throughmir29c AT wukerui lncrnaipwinhibitsgrowthofductalcarcinomainsitubydownregulatingid2throughmir29c AT wushihying lncrnaipwinhibitsgrowthofductalcarcinomainsitubydownregulatingid2throughmir29c AT tyagiabhishek lncrnaipwinhibitsgrowthofductalcarcinomainsitubydownregulatingid2throughmir29c AT zhaodan lncrnaipwinhibitsgrowthofductalcarcinomainsitubydownregulatingid2throughmir29c AT moyinyuan lncrnaipwinhibitsgrowthofductalcarcinomainsitubydownregulatingid2throughmir29c AT watabekounosuke lncrnaipwinhibitsgrowthofductalcarcinomainsitubydownregulatingid2throughmir29c |